Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes.

about

Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes.

Item

http://www.wikidata.org/entity/Q49166621

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Old and new calcimimetics for ...... nd relevant clinical outcomes.

@en

Old and new calcimimetics for ...... nd relevant clinical outcomes.

@nl

type

Item

label

Old and new calcimimetics for ...... nd relevant clinical outcomes.

@en

Old and new calcimimetics for ...... nd relevant clinical outcomes.

@nl

prefLabel

Old and new calcimimetics for ...... nd relevant clinical outcomes.

@en

Old and new calcimimetics for ...... nd relevant clinical outcomes.

@nl

P1476

Old and new calcimimetics for ...... nd relevant clinical outcomes.

@en

P2093

Catarina Meng

http://www.w3.org/2001/XMLSchema#string

Daniela Marques

http://www.w3.org/2001/XMLSchema#string

João M Frazão

http://www.w3.org/2001/XMLSchema#string

Luciano Pereira

http://www.w3.org/2001/XMLSchema#string

P2860

Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease

Chronic kidney disease: global dimension and perspectives.

Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.

The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.

Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.

Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study

P304

80-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CKJ/SFX125

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29423207

http://www.w3.org/2001/XMLSchema#string

P921

hyperparathyroidism

P932

5798074

http://www.w3.org/2001/XMLSchema#string